. Author manuscript; available in PMC: 2018 Nov 1.

Published in final edited form as: Expert Opin Biol Ther. 2017 Sep 11;17(11):1463–1470. doi: 10.1080/14712598.2017.1377178

Table 3.

Selected Trials of Obinituzumab and Other Agents

Trials	Phase	Dose* (mg)	Number	Treatment Arms	AE’s	Best Overall Response
Fisher K et. al. ⁶³ (CLL14 Trial)	III	O: 1000 mg V: 20–400 mg	13	O+V	Neutropenia: 66.7% (G 3/4: 58%) IRRs: 75% (G 3/4: 8%)	ORR: 100% CR: 58% MRD 92%
Amaya-Chanaga CI et al. ⁵⁹	IB/II	O: 1000 mg I: 420 mg	9	O+I	Neutropenia: 33% (G 3/4: 22%) IRRs: 11% (G 3/4: 0)	CR: 50% (N=1) PR:50% (N=1)
Von Tresckow J et al. ⁶⁴ (CLL2-BIG trial)	II	O: 1000 mg I: 420 mg	66	O+I	Neutropenia: 19% (G 3/4: 14%) IRRs: 33% (G 3/4: 2%)	ORR: 100% CR: 46% PR: 54 %
Cramer P. et al. ⁶⁵ (CLL2-BAG Trial)	II	B: 70 mg/m² O: 1000 mg V: 20–400	66	B→O/V	Neutropenia: 11% IRRs: 9%	ORR: 97% CR: 38%
Jain N et al. ⁶⁶ (iFCG Trial)	II	FC O: 1000 mg I: 420 mg	23	iFCO	Neutropenia (G 3/4): 48%	ORR: 100% CR: 39%

Abbreviations: O/G, obinutuzumab; V, venetoclax; I, ibrutinib; B, bendamustine; FC, fludarabine/cyclophosphamide; CR, complete remission; PR, partial remission; ORR, objective response rate; MRD, minimal residual disease; IRRs, infusion-related reactions.